Annexon (ANNX) Other financing activities (2021 - 2026)
Annexon (ANNX) posted quarterly Other financing activities of $936000.0 for Q1 2026, up 1409.68% year-over-year from $62000.0 in Q1 2025, and down 2.4% quarter-over-quarter from $959000.0 in Q4 2025.
Annexon (ANNX) Other financing activities (2021 - 2026) Analysis & Trends
Annexon's Other financing activities history runs 6 years deep, the most recent figure standing at $936000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 1409.68% year-over-year to $936000.0; the TTM figure through Mar 2026 stood at $2.5 million (up 561.27% YoY), while the FY2025 annual figure was $1.6 million, up 31.41% from the prior year.
- Other financing activities for Q1 2026 stood at $936000.0, down from $959000.0 in the prior quarter.
- The five-year high for Other financing activities was $959000.0 in Q4 2025, with the low at -$702000.0 in Q2 2024.
- The 5-year median for Other financing activities is $115500.0 (2023), against an average of $247312.5.
- The sharpest annual moves came in 2023 and 2026: Other financing activities sank 2818.75% in 2023, then surged 1409.68% in 2026.
- Annexon's Other financing activities stood at $16000.0 in 2022, then tumbled by 2818.75% to -$435000.0 in 2023, then surged by 172.18% to $314000.0 in 2024, then soared by 205.41% to $959000.0 in 2025, then declined by 2.4% to $936000.0 in 2026.
- Business Quant data shows ANNX's Other financing activities at $936000.0 in Q1 2026, $959000.0 in Q4 2025, and $478000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | 936,000.00 |
| Mar 31, 2026 | 936,000.00 |
| Dec 31, 2025 | 959,000.00 |
| Dec 31, 2025 | 959,000.00 |
| Sep 30, 2025 | 478,000.00 |
| Sep 30, 2025 | 478,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 314,000.00 |
| Dec 31, 2024 | 314,000.00 |
| Sep 30, 2024 | 703,000.00 |
| Sep 30, 2024 | 703,000.00 |
| Jun 30, 2024 | -702,000.00 |
| Jun 30, 2024 | -702,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |